Investigation Underway: Aquestive Therapeutics, Inc. (AQST) - Contact Levi & Korsinsky Over Securities Law Violations

Group 1 - Aquestive Therapeutics, Inc. is under investigation by Levi & Korsinsky for potential violations of federal securities laws following an FDA letter identifying deficiencies in its NDA application for Anaphylm [1] - On January 9, 2026, the FDA's letter precluded labeling discussions and post-market commitments for Anaphylm, which is intended for the emergency treatment of anaphylaxis [1] - Following this news, Aquestive's stock price dropped by $2.18, a decline of 35.1%, opening at $4.03 [2] Group 2 - Levi & Korsinsky LLP has a strong reputation in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [3] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [3]